N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer. 2006

Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.

OBJECTIVE N-acetylglucosaminyltransferase V (GnT-V) is an enzyme that catalyzes beta1-6 branching of N-acetylglucosamine on asparagine (N)-linked oligosaccharides (N-glycan) of cell proteins. We examined the relationship between GnT-V expression and clinicopathologic features of the patients with bladder cancer. METHODS We immunohistochemically examined GnT-V expression in paraffin-embedded bladder cancer specimen using anti-GnT-V monoclonal antibody. We compared GnT-V expression with cause-specific survival of the patients with bladder cancer treated by radical cystectomy. Kaplan-Meier survival curves were generated to show the cause-specific survival. Univariate and multivariate analyses were carried out to compare GnT-V expression with other clinical and pathologic variables. We also evaluated mRNA expression of GnT-V and N-linked oligosaccharide structure in bladder cancer specimens. RESULTS Immunohistochemistry revealed that GnT-V expression inversely correlated with tumor grade and stage. The incidence of positive GnT-V expression in bladder cancer was significantly higher in low-grade/superficial cancer than in high-grade/invasive cancer. The patients whose tumor was positive for GnT-V survived significantly longer than those whose tumor was negative for GnT-V. Univariate and multivariate analyses revealed that GnT-V expression was an independent predictor of prognosis of the patient. The expression of GnT-V mRNA determined by reverse transcription-PCR was consistent with the results with immunohistochemistry for tumor samples. Carbohydrate structural analysis revealed that superficial bladder cancer is rich in branched N-linked oligosaccharides, for which biosynthesis GnT-V is responsible. CONCLUSIONS GnT-V and its resultant beta1-6 branching N-linked oligosaccharides are closely related to low malignant potential and good prognosis of the patients with bladder cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
January 2008, International journal of oncology,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
December 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
January 1994, Advances in experimental medicine and biology,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
January 2007, Journal of cellular biochemistry,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
August 2018, Nature communications,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
December 2007, British journal of cancer,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
February 2013, Cancer science,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
March 2014, International journal of oncology,
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
May 1987, Science (New York, N.Y.),
Hirofumi Ishimura, and Toshiko Takahashi, and Hiroaki Nakagawa, and Shin-Ichiro Nishimura, and Yoichi Arai, and Yohei Horikawa, and Tomonori Habuchi, and Eiji Miyoshi, and Atsushi Kyan, and Shigeru Hagisawa, and Chikara Ohyama
January 2006, The Journal of urology,
Copied contents to your clipboard!